This content is machine translated Advanced high-grade serous ovarian cancer. HRD+ tumors: first PARP inhibitor approved for first-line maintenance therapy As the first and only PARP inhibitor, olaparib was recently approved by swissmedic for first-line maintenance therapy in patients with advanced, HRD-positive ovarian cancer. The addition of olaparib to bevacizumab resulted…
View Post 8 min This content is machine translated Ovarian Cancer Treatment 2019: Important and new Ovarian cancer has become a chronic disease. Therapy sequences with surgery, additive and palliative systemic therapies, plus maintenance therapies in different lineages are complex. Discussing current data helps to translate…
